Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin for GVHD Prevention
NCT00506922Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2000
- Primary completion
- Nov 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pentostatin in graft-versus-host disease (GVHD) (5 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Patients Without GVHD at 100 Days. Started Sep 2000; status: completed.
02
Drugs
pentostatin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00506922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506922.